{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:19:27Z","timestamp":1761016767775},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2008,5,21]],"date-time":"2008-05-21T00:00:00Z","timestamp":1211328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1186\/cc6819","type":"journal-article","created":{"date-parts":[[2008,5,21]],"date-time":"2008-05-21T19:51:33Z","timestamp":1211399493000},"source":"Crossref","is-referenced-by-count":26,"title":["An overview of harms associated with \u03b2-lactam antimicrobials: where do the carbapenems fit in?"],"prefix":"10.1186","volume":"12","author":[{"suffix":"Jr","given":"Robert C","family":"Owens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,21]]},"reference":[{"key":"6252_CR1","unstructured":"Food and Drug Administration: FDA announces label and indication changes for the antibiotic Ketek. [ http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2007\/NEW01561.html ]"},{"key":"6252_CR2","unstructured":"Food and Drug Administration Centers for Drug Evaluation and Research: Clinical therapeutics and recognition of drug induced disease. [ http:\/\/www.fda.gov\/medwatch\/articles\/dig\/ceart.pdf ]"},{"key":"6252_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1086\/340740","volume":"35","author":"JL Robinson","year":"2002","unstructured":"Robinson JL, Hameed T, Carr S: Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic. Clin Infect Dis 2002, 35: 26-31. 10.1086\/340740","journal-title":"Clin Infect Dis"},{"key":"6252_CR4","first-page":"299","volume-title":"Principles and Practice of Infectious Diseases","author":"ME Weiss","year":"2000","unstructured":"Weiss ME, Adkinson NF: \u03b2-Lactam allergy. In Principles and Practice of Infectious Diseases. Edited by: Mandell GL, Bennett JE, Dolin R. Philadelphia, PA: Churchill Livingston; 2000:299-305."},{"key":"6252_CR5","unstructured":"US FDA website [ http:\/\/www.fda.gov ]"},{"key":"6252_CR6","volume-title":"Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 to 21 September 2007","author":"R Maroko","year":"2007","unstructured":"Maroko R, Cooper A, Dukart G, Dartios H: Results of phase 3 study comparing a tigecycline regimen with an imipenem\/cilastatin regimen in treatment of patients with hospital acquired pneumonia [poster L-730]. In Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 17 to 21 September 2007. Washington, DC: American Society of Microbiology; 2007."},{"key":"6252_CR7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"KE Lasser","year":"2002","unstructured":"Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002, 287: 2215-2220. 10.1001\/jama.287.17.2215","journal-title":"JAMA"},{"key":"6252_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJM199102073240605","volume":"324","author":"LL Leape","year":"1991","unstructured":"Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H: The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991, 324: 377-384.","journal-title":"N Engl J Med"},{"key":"6252_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrd1108","volume":"2","author":"B Fermini","year":"2003","unstructured":"Fermini B, Fossa AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003, 2: 439-447. 10.1038\/nrd1108","journal-title":"Nat Rev Drug Discov"},{"key":"6252_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","volume":"64","author":"RC Owens Jr","year":"2004","unstructured":"Owens RC Jr: QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004, 64: 1091-1124. 10.2165\/00003495-200464100-00005","journal-title":"Drugs"},{"key":"6252_CR11","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1086\/508873","volume":"43","author":"RC Owens Jr","year":"2006","unstructured":"Owens RC Jr, Nolin TD: Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006, 43: 1603-1611. 10.1086\/508873","journal-title":"Clin Infect Dis"},{"key":"6252_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1086\/339075","volume":"34","author":"JS Bertino Jr","year":"2002","unstructured":"Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB: Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002, 34: 861-863. 10.1086\/339075","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"6252_CR13","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","volume":"41","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr, Ambrose PG: Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005,41(suppl 2):S144-S157. 10.1086\/428055","journal-title":"Clin Infect Dis"},{"key":"6252_CR14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.amjcard.2004.02.034","volume":"93","author":"J Morganroth","year":"2004","unstructured":"Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA, Sethuraman VS, Montague TH: Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004, 93: 1378-1383. A6. 10.1016\/j.amjcard.2004.02.034","journal-title":"Am J Cardiol"},{"key":"6252_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1592\/phco.2005.25.10.1291","volume":"25","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr: Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy 2005, 25: 1291-1295. 10.1592\/phco.2005.25.10.1291","journal-title":"Pharmacotherapy"},{"key":"6252_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1476-5381.1996.tb15201.x","volume":"117","author":"N Maeda","year":"1996","unstructured":"Maeda N, Tamagawa T, Niki I, Miura H, Ozawa K, Watanabe G, Nonogaki K, Uemura K, Iguchi A: Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996, 117: 372-376.","journal-title":"Br J Pharmacol"},{"key":"6252_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1592\/phco.26.3.299","volume":"26","author":"RC Owens","year":"2006","unstructured":"Owens RC: Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26: 299-311. 10.1592\/phco.26.3.299","journal-title":"Pharmacotherapy"},{"key":"6252_CR18","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1086\/521861","volume":"46","author":"DN Gerding","year":"2008","unstructured":"Gerding DN, Muto CA, Owens RC Jr: Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008, 46: S43-S49. 10.1086\/521861","journal-title":"Clin Infect Dis"},{"key":"6252_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00003495-200767040-00001","volume":"67","author":"RC Owens","year":"2007","unstructured":"Owens RC: Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 2007, 67: 487-502. 10.2165\/00003495-200767040-00001","journal-title":"Drugs"},{"key":"6252_CR20","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1086\/521859","volume":"46","author":"RC Owens Jr","year":"2008","unstructured":"Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46: S19-S31. 10.1086\/521859","journal-title":"Clin Infect Dis"},{"key":"6252_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1086\/382084","volume":"38","author":"DN Gerding","year":"2004","unstructured":"Gerding DN: Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004, 38: 646-648. 10.1086\/382084","journal-title":"Clin Infect Dis"},{"key":"6252_CR22","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1128\/AAC.01623-06","volume":"51","author":"DW Hecht","year":"2007","unstructured":"Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN: In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, 51: 2716-2719. 10.1128\/AAC.01623-06","journal-title":"Antimicrob Agents Chemother"},{"key":"6252_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0195-6701(98)90019-6","volume":"40","author":"GE Bignardi","year":"1998","unstructured":"Bignardi GE: Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40: 1-15. 10.1016\/S0195-6701(98)90019-6","journal-title":"J Hosp Infect"},{"issue":"suppl","key":"6252_CR24","doi-asserted-by":"publisher","first-page":"77S","DOI":"10.1016\/j.diagmicrobio.2006.12.012","volume":"57","author":"RC Owens Jr","year":"2007","unstructured":"Owens RC Jr, Ambrose PG: Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. Diagn Microbiol Infect Dis 2007,57(suppl):77S-83S. 10.1016\/j.diagmicrobio.2006.12.012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"6252_CR25","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1056\/NEJMoa054408","volume":"355","author":"KM Itani","year":"2006","unstructured":"Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA: Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006, 355: 2640-2651. 10.1056\/NEJMoa054408","journal-title":"N Engl J Med"},{"key":"6252_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/BF01691147","volume":"15","author":"G Bodey","year":"1996","unstructured":"Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E: Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996, 15: 625-634. 10.1007\/BF01691147","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6252_CR27","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1086\/496986","volume":"41","author":"J P\u00e9pin","year":"2005","unstructured":"P\u00e9pin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41: 1254-1260. 10.1086\/496986","journal-title":"Clin Infect Dis"},{"key":"6252_CR28","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1086\/516613","volume":"44","author":"RC Owens Jr","year":"2007","unstructured":"Owens RC Jr, Nolin TD: QT reply to Chinello and Petrosillo [letter]. Clin Infect Dis 2007, 44: 1389-1391. 10.1086\/516613","journal-title":"Clin Infect Dis"},{"key":"6252_CR29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa040582","volume":"351","author":"WA Ray","year":"2004","unstructured":"Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM: Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004, 351: 1089-1096. 10.1056\/NEJMoa040582","journal-title":"N Engl J Med"},{"key":"6252_CR30","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1345\/aph.1E187","volume":"38","author":"M Segarra-Newnham","year":"2004","unstructured":"Segarra-Newnham M, Tagoff SS: Probable vancomycin-induced neutropenia. Ann Pharmacother 2004, 38: 1855-1859. 10.1345\/aph.1E187","journal-title":"Ann Pharmacother"},{"key":"6252_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4065\/74.7.730","volume":"74","author":"JD Smilack","year":"1999","unstructured":"Smilack JD: Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999, 74: 730-734.","journal-title":"Mayo Clin Proc"},{"key":"6252_CR32","first-page":"299","volume-title":"Principles and Practice of Infectious Diseases","author":"HF Chambers","year":"2000","unstructured":"Chambers HF: Penicillins. In Principles and Practice of Infectious Diseases. Edited by: Mandell GL, Bennett JE, Dolin R. Philadelphia, PA: Churchill Livingston; 2000:299-305."},{"key":"6252_CR33","first-page":"299","volume-title":"Principles and Practice of Infectious Diseases","author":"AW Karchmer","year":"2000","unstructured":"Karchmer AW: Cephalosporins. In Principles and Practice of Infectious Diseases. Edited by: Mandell GL, Bennett JE, Dolin R. Philadelphia, PA: Churchill Livingston; 2000:299-305."},{"key":"6252_CR34","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1345\/aph.1D022","volume":"37","author":"DL Wilson","year":"2003","unstructured":"Wilson DL, Owens RC Jr, Zuckerman JB: Successful meropenem desensitization in a patient with cystic fibrosis. Ann Pharmacother 2003, 37: 1424-1428. 10.1345\/aph.1D022","journal-title":"Ann Pharmacother"},{"key":"6252_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1592\/phco.27.1.137","volume":"27","author":"WA Prescott Jr","year":"2007","unstructured":"Prescott WA Jr, Kusmierski KA: Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007, 27: 137-142. 10.1592\/phco.27.1.137","journal-title":"Pharmacotherapy"},{"key":"6252_CR36","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/320752","volume":"32","author":"DM Forrest","year":"2001","unstructured":"Forrest DM, Schellenberg RR, Thien VV, King S, Anis AH, Dodek PM: Introduction of a practice guideline for penicillin skin testing improves the appropriateness of antibiotic therapy. Clin Infect Dis 2001, 32: 1685-1690. 10.1086\/320752","journal-title":"Clin Infect Dis"},{"key":"6252_CR37","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1086\/317507","volume":"31","author":"SA McConnell","year":"2000","unstructured":"McConnell SA, Penzak SR, Warmack TS, Anaissie EJ, Gubbins PO: Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. Clin Infect Dis 2000, 31: 1512-1514. 10.1086\/317507","journal-title":"Clin Infect Dis"},{"key":"6252_CR38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1086\/382880","volume":"38","author":"WA Prescott Jr","year":"2004","unstructured":"Prescott WA Jr, DePestel DD, Ellis JJ, Regal RE: Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 2004, 38: 1102-1107. 10.1086\/382880","journal-title":"Clin Infect Dis"},{"key":"6252_CR39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/jac\/dkh454","volume":"54","author":"M Sodhi","year":"2004","unstructured":"Sodhi M, Axtell SS, Callahan J, Shekar R: Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother 2004, 54: 1155-1157. 10.1093\/jac\/dkh454","journal-title":"J Antimicrob Chemother"},{"key":"6252_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1056\/NEJM200002033420517","volume":"342","author":"HJ Chen","year":"2000","unstructured":"Chen HJ, Bloch KJ, Maclean JA: Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000, 342: 359-360. 10.1056\/NEJM200002033420517","journal-title":"N Engl J Med"},{"key":"6252_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1086\/338047","volume":"34","author":"NF Maraqa","year":"2002","unstructured":"Maraqa NF, Gomez MM, Rathore MH, Alvarez AM: Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis 2002, 34: 50-54. 10.1086\/338047","journal-title":"Clin Infect Dis"},{"key":"6252_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1592\/phco.22.9.794.34066","volume":"22","author":"SC Nicholson","year":"2002","unstructured":"Nicholson SC, Webb CD, Moellering RC Jr: Antimicrobial-associated acute hepatitis. Pharmacotherapy 2002, 22: 794-796. 10.1592\/phco.22.9.794.34066","journal-title":"Pharmacotherapy"},{"key":"6252_CR43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/106002809703100213","volume":"31","author":"T Vial","year":"1997","unstructured":"Vial T, Biour M, Descotes J, Trepo C: Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother 1997, 31: 204-220.","journal-title":"Ann Pharmacother"},{"key":"6252_CR44","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0025-7125(05)70297-2","volume":"84","author":"RC Owens Jr","year":"2000","unstructured":"Owens RC Jr, Ambrose PG: Clinical use of the fluoroquinolones. Med Clin North Am 2000, 84: 1447-1469. 10.1016\/S0025-7125(05)70297-2","journal-title":"Med Clin North Am"},{"key":"6252_CR45","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1086\/382356","volume":"38","author":"N Rao","year":"2004","unstructured":"Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL: Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 2004, 38: 1058-1064. 10.1086\/382356","journal-title":"Clin Infect Dis"},{"key":"6252_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jac\/27.1.95","volume":"27","author":"BS Charak","year":"1991","unstructured":"Charak BS, Louie R, Malloy B, Twomey P, Mazumder A: The effect of amphotericin B, aztreonam, imipenem and cephalosporins on the bone marrow progenitor cell activity. J Antimicrob Chemother 1991, 27: 95-104. 10.1093\/jac\/27.1.95","journal-title":"J Antimicrob Chemother"},{"key":"6252_CR47","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0002-9343(88)90071-X","volume":"84","author":"G Calandra","year":"1988","unstructured":"Calandra G, Lydick E, Carrigan J, Weiss L, Guess H: Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem\/cilastatin. Am J Med 1988, 84: 911-918. 10.1016\/0002-9343(88)90071-X","journal-title":"Am J Med"},{"key":"6252_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0736-4679(97)00242-4","volume":"16","author":"EA Sullivan","year":"1998","unstructured":"Sullivan EA, Geoffroy P, Weisman R, Hoffman R, Frieden TR: Isoniazid poisonings in New York City. J Emerg Med 1998, 16: 57-59. 10.1016\/S0736-4679(97)00242-4","journal-title":"J Emerg Med"},{"key":"6252_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/sj.mt.6300069","volume":"15","author":"J Yang","year":"2007","unstructured":"Yang J, Teng Q, Federici T, Najm I, Chabardes S, Moffitt M, Alexopoulos A, Riley , Boulis NM: Viral clostridial light chain gene-based control of penicillin-induced neocortical seizures. Mol Ther 2007, 15: 542-551. 10.1038\/sj.mt.6300069","journal-title":"Mol Ther"},{"key":"6252_CR50","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/archinte.1989.00390080131029","volume":"149","author":"RH Eng","year":"1989","unstructured":"Eng RH, Munsif AN, Yangco BG, Smith SM, Chmel H: Seizure propensity with imipenem. Arch Intern Med 1989, 149: 1881-1883. 10.1001\/archinte.149.8.1881","journal-title":"Arch Intern Med"},{"key":"6252_CR51","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O","volume":"82","author":"II Raad","year":"1998","unstructured":"Raad II, bi-Said D, Rolston KV, Karl CL, Bodey GP: How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Cancer 1998, 82: 2449-2458. 10.1002\/(SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O","journal-title":"Cancer"},{"key":"6252_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1128\/AAC.27.5.745","volume":"27","author":"BA Zajac","year":"1985","unstructured":"Zajac BA, Fisher MA, Gibson GA, MacGregor RR: Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. Antimicrob Agents Chemother 1985, 27: 745-748.","journal-title":"Antimicrob Agents Chemother"},{"key":"6252_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00006454-199102000-00009","volume":"10","author":"VK Wong","year":"1991","unstructured":"Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS: Imipenem\/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991, 10: 122-125.","journal-title":"Pediatr Infect Dis J"},{"key":"6252_CR54","volume-title":"Primaxin\u00ae IV (Imipenem and Cilastatin for Injection) Package Insert","author":"Merck and Co","year":"2005","unstructured":"Merck and Co: Primaxin\u00ae IV (Imipenem and Cilastatin for Injection) Package Insert. Whitehouse Station, NJ: Merck and Co; 2005."},{"key":"6252_CR55","volume-title":"Merrem\u00ae IV (Meropenem for Injection) Package Insert","author":"AstraZeneca","year":"2005","unstructured":"AstraZeneca: Merrem\u00ae IV (Meropenem for Injection) Package Insert. Wilmington, DE: AstraZeneca; 2005."},{"key":"6252_CR56","volume-title":"Invanz\u00ae (Ertapenem for Injection) Package Insert","author":"Merck and Co","year":"2005","unstructured":"Merck and Co: Invanz\u00ae (Ertapenem for Injection) Package Insert. Whitehouse Station, NJ: Merck and Co; 2005."},{"key":"6252_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","volume":"222","author":"M Horiuchi","year":"2006","unstructured":"Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K: Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006, 222: 114-124. 10.1016\/j.tox.2006.02.004","journal-title":"Toxicology"},{"key":"6252_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1592\/phco.23.3.369.32100","volume":"23","author":"KM Chow","year":"2003","unstructured":"Chow KM, Szeto CC, Hui ACF, Wong TYH, Li TL: Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003, 23: 369-373. 10.1592\/phco.23.3.369.32100","journal-title":"Pharmacotherapy"},{"key":"6252_CR59","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ndt\/gfm713","volume":"23","author":"J Sonck","year":"2008","unstructured":"Sonck J, Laureys G, Verbeelen D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008, 23: 966-970. 10.1093\/ndt\/gfm713","journal-title":"Nephrol Dial Transplant"},{"key":"6252_CR60","first-page":"S456","volume":"40","author":"RC Owens Jr","year":"2005","unstructured":"Owens RC Jr, Ambrose PG: Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005, 40: S456-69.","journal-title":"Clin Infect Dis"},{"key":"6252_CR61","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/jac\/49.3.445","volume":"49","author":"PG Ambrose","year":"2002","unstructured":"Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN: Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002, 49: 445-453. 10.1093\/jac\/49.3.445","journal-title":"J Antimicrob Chemother"},{"key":"6252_CR62","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","volume":"14","author":"DM Livermore","year":"2006","unstructured":"Livermore DM, Woodford N: The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter . Trends Microbiol 2006, 14: 413-420. 10.1016\/j.tim.2006.07.008","journal-title":"Trends Microbiol"},{"key":"6252_CR63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/j.1875-9114.1995.tb04366.x","volume":"15","author":"DN Fish","year":"1995","unstructured":"Fish DN, Piscitelli SC, Danziger LH: Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995, 15: 279-291.","journal-title":"Pharmacotherapy"},{"key":"6252_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1517\/13543784.11.4.529","volume":"11","author":"G Bonfiglio","year":"2002","unstructured":"Bonfiglio G, Russo G, Nicoletti G: Recent developments in carbapenems. Expert Opin Investig Drugs 2002, 11: 529-544. 10.1517\/13543784.11.4.529","journal-title":"Expert Opin Investig Drugs"},{"key":"6252_CR65","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001\/jama.290.19.2588","journal-title":"JAMA"},{"key":"6252_CR66","volume-title":"The Sanford Guide to Antimicrobial Therapy 2006 (Guide to Antimicrobial Therapy)","author":"DN Gilbert","year":"2006","unstructured":"Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA: The Sanford Guide to Antimicrobial Therapy 2006 (Guide to Antimicrobial Therapy). 36th edition. Sperryville, VA: Antimicrobial Therapy Inc; 2006.","edition":"36"},{"key":"6252_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/j.1552-4604.1988.tb05735.x","volume":"28","author":"GB Calandra","year":"1988","unstructured":"Calandra GB, Ricci FM, Wang C, Brown KR: The efficacy results and safety profile of imipenem\/cilastatin from the clinical research trials. J Clin Pharm 1988, 28: 120-127.","journal-title":"J Clin Pharm"},{"key":"6252_CR68","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","volume":"43","author":"Y Carmeli","year":"1999","unstructured":"Carmeli Y, Troillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43: 1379-1382.","journal-title":"Antimicrob Agents Chemother"},{"key":"6252_CR69","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/01.CCM.0000215517.51187.CA","volume":"34","author":"B Georges","year":"2006","unstructured":"Georges B, Conil JM, Dubouix A, Archambaud M, Bonnet E, Saivin S, Lauwers-Cances V, Cristini C, Cougot P, Decun JF, Mathe O, Chabonon G, Marty N, Sequin T, Houin G: Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006, 34: 1636-1641. 10.1097\/01.CCM.0000215517.51187.CA","journal-title":"Crit Care Med"},{"key":"6252_CR70","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1086\/322677","volume":"33","author":"S Harbarth","year":"2001","unstructured":"Harbarth S, Harris AD, Carmeli Y, Samore MH: Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001, 33: 1462-1468. 10.1086\/322677","journal-title":"Clin Infect Dis"},{"key":"6252_CR71","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1086\/338237","volume":"34","author":"AD Harris","year":"2002","unstructured":"Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC: Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002, 34: 340-345. 10.1086\/338237","journal-title":"Clin Infect Dis"},{"key":"6252_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1128\/AAC.26.5.673","volume":"26","author":"DJ Winston","year":"1984","unstructured":"Winston DJ, McGrattan MA, Busuttil RW: Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984, 26: 673-677.","journal-title":"Antimicrob Agents Chemother"},{"key":"6252_CR73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/jac\/47.3.247","volume":"47","author":"DM Livermore","year":"2001","unstructured":"Livermore DM: Of Pseudomonas , porins, pumps and carbapenems. J Antimicrob Chemother 2001, 47: 247-250. 10.1093\/jac\/47.3.247","journal-title":"J Antimicrob Chemother"},{"key":"6252_CR74","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1378\/chest.128.4.2336","volume":"128","author":"JL Blumer","year":"2005","unstructured":"Blumer JL, Saiman L, Konstan MW, Melnick D: The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005, 128: 2336-2346. 10.1378\/chest.128.4.2336","journal-title":"Chest"},{"key":"6252_CR75","first-page":"317","volume-title":"Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro BM, Drusano GL: Practical application of pharmacodynamic principles to optimize therapy and treat resistant organisms: a focus on beta-lactam antibiotics. In Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. Edited by: Owens RC Jr, Lautenbach E. Informa Healthcare; 2008:317-335."},{"key":"6252_CR76","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1128\/AAC.49.1.461-463.2005","volume":"49","author":"BM Lomaestro","year":"2005","unstructured":"Lomaestro BM, Drusano GL: Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005, 49: 461-463. 10.1128\/AAC.49.1.461-463.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"6252_CR77","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1093\/clinids\/7.Supplement_3.S528","volume":"7","author":"C Wang","year":"1985","unstructured":"Wang C, Calandra GB, Aziz MA, Brown KR: Efficacy and safety of imipenem\/cilastatin: a review of worldwide clinical experience. Rev Infect Dis 1985,7(suppl 3):S528-S536.","journal-title":"Rev Infect Dis"},{"key":"6252_CR78","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/AAC.46.8.2327-2332.2002","volume":"46","author":"E Viaene","year":"2002","unstructured":"Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM: Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002, 46: 2327-2332. 10.1128\/AAC.46.8.2327-2332.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"6252_CR79","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM195303192481201","volume":"238","author":"H Eagle","year":"1953","unstructured":"Eagle H, Fleischman R, Levy M: Continuous versus discontinuous therapy with penicillin. N Engl J Med 1953, 238: 481-486.","journal-title":"N Engl J Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/cc6819.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/cc6819\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/cc6819.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T15:30:51Z","timestamp":1708961451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc6819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,21]]},"references-count":79,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["6252"],"URL":"https:\/\/doi.org\/10.1186\/cc6819","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,21]]},"article-number":"S3"}}